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Key points: 
• HPV impacts on the health of both sexes; vaccination is most effective when given 
prior to sexual contact.  
• Adolescent males appear to have limited knowledge of HPV and the HPV vaccine.  
• Research into vaccine acceptance is complicated due to the lack of definition and 
validated measurement tools.  
• More prospective longitudinal research is needed in order to develop effective 
intervention strategies.  
• The Precaution Adoption Process Model may be beneficial to guide research into 
vaccine acceptance.  
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Human papillomavirus (HPV) is one of the most common sexually transmitted infections 
worldwide [1]. It is so common that nearly all sexually active men and women will be exposed 
to it at some point in their lives. HPV can be passed from one person to another even when 
there are no visible signs and symptoms. Most people are able to clear the infection themselves 
with no lasting harm, but for some the virus persists and can lead to a number of health 
problems. HPV infection is well-recognised as a causative agent in cervical cancer, but it is 
also associated with other anogenital tumours, oropharyngeal cancers, and genital warts, 
meaning that it also has serious health consequences in males and females [2]. Despite HPV’s 
impact on the health of both sexes, only the United States (US), Australia, Austria, Israel, and 
two Canadian provinces currently recommend a gender neutral vaccination. Switzerland has 
recently made a recommendation that the vaccine should be ‘gender neutral’ and is currently 
considering offering the vaccine to both sexes.  Despite this, there is substantial debate around 
the inclusion of males in HPV vaccination programmes. Many European countries do not 
include men, and focus on achieving a high coverage in females to promote herd protection, 
i.e. a reduction in the risk of infection in males due to reduced exposure as a result of female 
vaccination. There is some emerging evidence that this is the case, an analysis of female only 
vaccination programmes in nine countries with high female vaccination rates found a reduction 
in the number of boys with genital warts of around one third [3]. The incremental benefit of 
extending the vaccine to males is indeed highly dependent on coverage in females. With a low 
uptake in girls, the benefit of vaccinating boys is easily demonstrated. With a more than 70% 
uptake in females, the gender neutral vaccine appears less cost effective, however, a European 
study assessing the benefit of male vaccination in all carcinomas that have an established causal 
link with HPV demonstrated that the vaccination of 12 year old boys and girls would be 
associated with substantial additional clinical benefits in terms of reduced incidence of HPV-
related genital warts and carcinomas versus a girls only vaccination [4], this additional benefit 
was noted even with a high vaccine uptake.  
 
A female only vaccination strategy does however leave a number of men vulnerable to HPV 
infection, particularly men who have sex with other men (MSM), and men who have sex with 
unvaccinated females. A proposed solution could be to offer the vaccine to MSM at a sexual 
health clinic; however, for the HPV vaccine to be most effective it should be given in 
adolescence, before exposure to HPV through sexual contact. Data on immunogenicity in 
males demonstrated that seroconversion and antibody titers are higher in males aged 9-15 years 
than males aged 16-26 [5]. Most MSM are likely to have had multiple sexual partners with 
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increased risk of HPV acquisition before they attend a sexual health clinic [6]. It is our opinion 
that the most practical and ethical solution to the problem is to offer HPV vaccination to both 
adolescent males and females.  
 
It is therefore imperative to understand the knowledge, awareness and attitudes of adolescent 
boys to HPV and HPV vaccination to ensure uptake is maximised and both boys and girls are 
protected against HPV-related cancers in the future. This is vital given that, for example, in the 
US, where a gender neutral vaccine is offered, there is evidence to suggest that vaccine uptake 
in adolescent males is low; in 2012 only 20.8% boys aged 13 – 17 received at least one dose, 
with only 6.8% receiving the full three dose schedule [7].   
 
In the past five years there has been a proliferation of studies examining knowledge and 
awareness of HPV in adolescent boys (which is likely reflective of changes in various policies 
to recommend a gender neutral vaccine strategy). The majority of studies have been cross-
sectional and conducted in the US, UK, Australia and Canada, but other European, Asian and 
African countries have also examined the issue and it would appear that currently adolescent 
boys’ knowledge and awareness of HPV is low [8].  
 
Policy and Practice recommendations 
Insufficient knowledge of HPV in adolescent boys may be reflective of many countries’ 
information campaigns being targeted to females only with a clear focus on cervical cancer. 
What may be needed is better health education and public information to maximise public 
awareness that HPV affects both men and women and should be the concern of both sexes.  
 
Although knowledge it low, it is important to note that knowledge is not always predictive of 
vaccine acceptance and uptake. In China, despite HPV knowledge being poor, a large majority 
of females were accepting of vaccination [9]. There is therefore an opportunity for education 
to extend beyond vaccination to transmission and other prevention measures. As knowledge 
and acceptance are not always correlated, i.e. an adolescent may consider vaccination without 
adequate knowledge, health care professionals responsible for vaccination should use the 
opportunity to inform adolescents about HPV and its associated cancers.  
 
Countries with school based programmes such as the UK have achieved high female 
vaccination rates, and may also achieve high male rates if a gender neutral vaccination was 
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introduced. In the absence of such a programme, it can be challenging to achieve high rates 
and to ensure all doses are received in a timely manner. The US, for example, may never 
achieve high female or male vaccination rates. It is even more imperative therefore to 
accurately understand vaccine acceptance to order to improve uptake.  
 
Research recommendations 
The cross-sectional nature of the bulk of the research to date makes it difficult to determine if 
vaccine acceptance or intent to vaccinate leads to actual vaccine uptake. Prospective 
longitudinal studies would be more informative providing data on factors that influenced the 
move from vaccine intention to uptake.  
 
Few studies on vaccine acceptance in adolescent boys are guided by a theoretical framework 
around decision making or behaviour change; this makes the identification and exploration of 
factors that influence vaccine uptake difficult. This is vital if we are to determine how to 
increase vaccine acceptance and uptake. A theoretical framework such as the Precaution 
Adoption Process Model (PAPM), a model of behaviour change with six stages of decision-
making [10], may be beneficial for work of this nature. The PAPM categorises individuals as 
1) unaware 2) unengaged, 3) undecided 4) decided not to act 5) decided to act 6) acting. This 
model applied in a longitudinal survey would allow for the crucial identification of factors that 
caused the change in health behaviour. The PAPM is suited to research in vaccine acceptance 
and uptake as it identifies those who are aware of the vaccine but decided not to act. The 
categorisation of individuals who have decided to act and those individuals who have acted 
(i.e. received the vaccine) allows the crucial identification of factors that lead individuals to 
receive the vaccine. It is likely that a different intervention would be needed for individuals at 
different stages of the PAPM. For example, someone is stage 1 (unaware) would benefit most 
from awareness raising interventions in the media or from health care professionals; someone 
who has decided to act needs assistance in accessing the vaccine.  
 
Research in the area is further complicated as there is currently no definition of vaccine 
acceptance, and no universally accepted tool for its measurement. This makes comparison of 
studies problematic as the outcome of interest is measured in various ways, making it difficult 
to draw conclusions and recommendations and to develop methods to enhance vaccine 
acceptance. 
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Policy makers are under increasing pressure in the UK, and other countries to consider the 
merit of a gender neutral vaccination. This correspondence does not aim to provide a scientific 
opinion on whether to implement the vaccine or not.  It does however highlight the importance 
of understanding vaccine acceptance in adolescent boys to enhance the uptake of vaccines in 
this population group, should a decision to implement a gender neutral vaccine be reached or 
have already been made.   
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